UCB Canada remains dedicated to helping patients and working collaboratively with CDA-AMC following draft recommendation for (Pr)BIMZELX® for hidradenitis suppurativa (HS)

UCB Canada Inc. respectfully disagrees with the draft recommendation issued by the Canadian Drug Agency (CDA-AMC) regarding PrBIMZELX® (bimekizumab injection) for the treatment of adults living with ...
Pharmabiz

NMPA accepts Akeso’s supplemental New Drug Application for gumokimab to treat active ankylosing spondylitis

NMPA accepts Akeso’s supplemental New Drug Application for gumokimab to treat active ankylosing spondylitis: Hong Kong Wednesday, January 21, 2026, 12:00 Hrs [IST] Akeso Inc, a ...
The Manila Times

Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis

Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing ...
Medscape

When Eye Problems Signal a Wider Immune Issue and Vice Versa

Patients with immune-mediated diseases face a high risk for incident uveitis, and those with uveitis face a high risk of ...
Scientific Research Publishing

Necrotizing Sarcoid Granulomatosis with Concurrent Ankylosing Spondylitis: A Case Mimicking Pulmonary Tuberculosis ()

Histologic tuberculosis eventually turned out to be necrotizing sarcoid granulomatosis, a rare disease. A retired TB ward nurse with recurrent uveitis, a positive TST, pulmonary masses and skeletal ...
FierceBiotech

Akeso scores twice in pair of phase 3 trials, teeing up regulatory submission in China

Akeso is adding a pair of late-stage wins to its scorecard in both ankylosing spondylitis and atopic dermatitis while also teeing up a new drug submission for one of the candidates. The Hong ...
Rolling Out

Ankylosing spondylitis affects women differently than men

For decades, ankylosing spondylitis was considered a man’s disease, but new research reveals something shocking: ankylosing spondylitis hits women differently and nearly as frequently as men, yet ...
News Medical

Safeguarding your spinal health

The first Saturday of May each year marks World Ankylosing Spondylitis (AS) Day, raising awareness of the 54 million patients globally living with spinal rigidity, morning stiffness and pain, bone ...
centerforbiosimilars

Data Show Comparable Efficacy, Added Cost Benefit With Adalimumab Biosimilar vs Humira

Biosimilar IBI303 offers comparable effectiveness to Humira for ankylosing spondylitis, providing significant cost savings and improved patient retention rates. Patients with ankylosing spondylitis ...
sambadenglish

Understanding Back Pain and Ankylosing Spondylitis: A Wake-Up Call

As we mark World Ankylosing Spondylitis Day on 03rd May 2025, it’s time to shine a spotlight on a frequently misunderstood cause of chronic back pain and help raise awareness among patients and ...
thecardiologyadvisor.com

TNF Inhibitors Lower Cardiovascular Event Risks in Ankylosing Spondylitis

Exposure to tumor necrosis factor inhibitors was associated with a lower risk for incident myocardial infarction or stroke among patients with ankylosing spondylitis. Tumor necrosis factor (TNF) ...